Dow Up0.00% Nasdaq Up0.09%

Curis, Inc. (CRIS)

1.48 Down 0.04(2.63%) Nov 28, 1:00PM EST
ProfileGet Profile for:
Curis, Inc.
4 Maguire Road
Lexington, MA 02421
United States - Map
Phone: 617-503-6500
Fax: 617-503-6501

Index Membership:N/A
Full Time Employees:33

Business Summary 

Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Curis, Inc.

Corporate Governance 
Curis, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Ali Fattaey Ph.D., 49
Chief Exec. Officer, Pres and Director
Mr. Daniel R. Passeri MSc., J.D., 53
Vice Chairman and Strategic Advisor
Mr. Michael P. Gray , 43
Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Sec.
Mr. Mark W. Noel , 55
VP of Technology Management & Intellectual Property
Dr. Jaye Viner M.D., MPH, 57
Chief Medical Officer and Exec. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders